Leukemia Clinical Trials

Showing 1441-1460 of 5,235 trials

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

NCT06612151

This study was designed to compare the efficacy and safety of YL201 with Topotecan Hydrochloride in subjects with relapsed small cell lung cancer (SCLC).

Small Cell Lung Cancer

MediLink Therapeutics (Suzhou) Co., Ltd.438 participantsStarted Dec 2024

Guangzhou, Guangdong, China

RECRUITINGPhase 1

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

NCT06613009

The main purpose of this study is to evaluate the safety and tolerability of IBI3009 and to determine the maximum tolerated dose (MTD) and/or the recommended dose for expansion (RDE) of IBI3009.

Small Cell Lung Cancer

Innovent Biologics (Suzhou) Co. Ltd.190 participantsStarted Dec 2024

Westmead, New South Wales, Australia • Wollongong, New South Wales, Australia • Heidelberg, Victoria, Australia +7 more locations

Not Yet RecruitingPhase 3

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

NCT06789796

The study is being conducted to evaluate the efficacy and safety of QL1706 versus QL1604 monotherapy as consolidation treatment in patients with limited-stage small cell lung cancer (LS-SCLC) who have not experienced disease progression after concurrent or sequential chemoradiotherapy. QL1706 (Iparomlimab and Tuvonralimab) is a single bifunctional MabPair product against PD-1 and CTLA-4. QL1604 is a monoclonal antibody against PD-1.

Small-cell Lung Cancer

Qilu Pharmaceutical Co., Ltd.636 participantsStarted Feb 2025

A Phase III Study of YL201 in Relapsed Small Cell Lung Cancer

Study of IBI3009 in Participants with Unresectable, Metastatic or Extensive-Stage Small Cell Lung Cancer

a Study of QL1706 or QL1604 in Patients With Limited-stage Small Cell Lung Cancer After Chemoradiotherapy.

Related Searches

(Concerto) Study of BLU-451 in Advanced Cancers With EGFR Exon 20 Insertion Mutations

Menu Label Noticeability

The Efficacy of Oral Dissolution Therapy (ODT), Extracorporeal Shock Wave Lithotripsy (ESWL), and Combined ESWL and ODT as Non-Invasive Modalities for Treating Small and Medium-Sized Radiolucent Renal Stones

Study of the Immunological Infiltrate and Immunometabolic Immunometabolic Profile of Patients with Acute Leukaemia

A Study of Olaparib and Low Dose Radiotherapy for Small Cell Lung Cancer

Immune Basis and Clinical Implications of Threshold-based Phenotypes of Peanut Allergy

Effects of Ventilator Hyperinflation Versus Vibrocompression in Mechanically Ventilated Patients

Detection of Small Fiber Neuropathy Using Skin Properties

A Pilot Study to Assess the Association Between Human Bioimpedance Measurements and Clinical Urodynamic Procedures

Circulating and Molecular Markers Involved in the Processes of Cachexia, Anorexia and Sarcopenia in Patients With NSCLC

Evaluation of UCPVax Plus Nivolumab as Second Line Therapy in Advanced Non Small Cell Lung Cancer

Microdevice In Ovarian, Fallopian Tube, And Peritoneal Cancer

Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

The Effect of Omalizumab on Allergic Rhinitis Symptoms: a Comparative Study

Analysis of Influencing Factors of High-Order Aberrations of SMILE with Lenticule Retained

Pulmonary Rehabilitation Before Lung Cancer Resection

Phase 1 Study of CK-301 (Cosibelimab) as a Single Agent in Subjects With Advanced Cancers